Testosterone Replacement For Men With Low Testosterone Improves Liver Function, Metabolic Syndrome
In middle-aged and older men with low testosterone levels, long-term testosterone replacement therapy greatly improves their fatty liver disease and their risk factors for cardiovascular disease and diabetes, a new study found. The results were presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C. Testosterone deficiency, which becomes more common with age, is linked not only to decreased libido but also to a number of medical problems.
Global Breakthrough In Treatment Of Dementia 'Within Reach' - Clinical Trial In Scotland Recruiting
A Glasgow-based medical research company is leading a worldwide sleep study which could radically reduce the symptoms associated with dementia. The groundbreaking trial, conducted by CPS Research, is the first of its kind to investigate the use of sleep hormone melatonin as an add on treatment for dementia. The study is already showing remarkable initial results in volunteers from Scotland...
Shingles Pain Treatment Will Benefit More Patients
The medicated pain relief plaster, (Versatis) is now approved by the Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland for patients suffering pain following shingles(1) http://www.scottishmedicines.org.uk/smc/5850.html.
The World Is Getting Better!
According to Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization, the world is getting better, no matter what critics say. Today’s life expectancy is the highest in human history. In Western countries, we ...
Risk Of A Second Breast Cancer May Be Increased By Rare ATM Gene Mutations Plus Radiation
Certain rare mutations in the ataxia telangiectasia mutated (ATM) gene, combined with radiation exposure, may increase a woman's risk of developing a second cancer in the opposite breast, according to a study published online March 19 in the Journal of the National Cancer Institute...
Agennix AG Announces Longer-Term Mortality Results From Talactoferrin Phase 2 Trial In Severe Sepsis
Agennix AG (FRANKFURT: AGX) (XETRA: AGX) announced longer-term mortality results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S...
Nausea And Vomiting Dramatically Reduced In Bone Marrow Transplant Patients
Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation. But a Loyola University Health System study has found the drug aprepitant can dramatically reduce both nausea and vomiting when combined with other anti-nausea drugs...
In the United States, CROs receive an estimated 60% of the clinical research outsourced from pharmaceutical companies.
Typically, large CROs compete on the basis of medical and scientific expertise in specific therapeutic areas; the ability to manage large-scale trials on a global basis with strategically located facilities, by providing medical database management capabilities, providing statistical and ...
Affymax Completes Enrollment In PEARL 1, The First Of Four Phase 3 Clinical Trials Of HematideT To Treat Anemia In Chronic Renal Failure Patient
Affymax, Inc. (Nasdaq:AFFY) announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, HematideT, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 475 non-dialysis patients from over 70 sites in the United States.
88.7% Of Ulcerative Colitis Patients In Remission Remained Relapse-Free At 12 Months With Once Daily Mezavant(R) XL (MMX Mesalazine)
Shire Limited, the global specialty biopharmaceutical company, announces that data published in Gut show that 64.4% of patients with mild to moderate ulcerative colitis (UC) who achieved clinical and endoscopic remission maintained this at 12 months when given two mesalazine 1200mg gastro-resistant, prolonged release tablets (Mezavant XL) once a day as a maintenance therapy.
Minocycline As A Promising Drug For Patients With Fragile X Syndrome Proposed By UCR Researchers
A UC Riverside-led team of biomedical scientists has found that a readily available drug called minocycline, used widely to treat acne and skin infections, can be used to treat Fragile X syndrome, the most common inherited cause of mental impairment and the most common cause of autism. The study's findings have already impacted future therapies, with the approval of a new clinical trial in Toronto, Canada, that will test minocycline in patients with Fragile X.
Use of the Cereprotex prior to and after the CABG procedures to substantially reduce or eliminate the effects of neuro-impairment.
Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in ...
Quintiles, SAS Announce Development Of First-Ever Clinical Trials Statistical Programming Certification
Quintiles, the world's No. 1 pharmaceutical services company, and SAS are developing a unique program to produce certified specialists in the use of SAS programming to evaluate clinical trials results, the companies announced today. The Quintiles-SAS Clinical Trials Statistical Programming Certification will certify that the successful candidate has shown that he or she has the expertise necessary to organize, analyze, and report clinical trials results.
Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.
Traumatic Brain Injury Collaboration Between Arbor Vita And WRAIR
The U.S. Department of Applied Neurobiology at the Walter Reed Army Institute of Research (WRAIR) and Arbor Vita Corporation (AVC) have signed a Cooperative Research and Development Agreement (CRADA) for research and development of treatments for traumatic brain injury (TBI). The alliance is based on discoveries made from a collaborative effort between AVC and NoNO Inc.
It is recommended that sponsor companies should first check what budget they can allocate, and then seek Clinqua Inc. expertise in achieving their goal.
It is an undesirable reality, but the development of pharmaceutical drugs is a costly undertaking. Yet, these costs are necessitated by the substantial investment of both time and resources of the companies in question. It stands to reason that if a company is willing to invest millions of ...
Researchers Identify Possible Imaging Method To Stratify Breast Cancer Without Biopsy
Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy. The findings were published online ahead of print in the Journal of Nuclear Medicine...
Gilead Announces Two-Year Data From Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
Risk Of HIV Infection In Heterosexual U.S. Men Reduced By Circumcision
A new U.S. study has found that being circumcised significantly reduced the risk of HIV infection in heterosexual African American men known to have been exposed to the virus. The findings complement those of recently reported clinical trials in Africa, where interventional use of adult male circumcision similarly reduced the risk of HIV infection in heterosexual men.
Clinproxy believes in the concept that cooperation with other CROs is the key to unlocking great accomplishments in the biopharmaceutical research industry.
Clinproxy is a Contract Research Organization www.clinproxy.com that is attempting to change the idea that has overwhelmed the Biopharmaceutical Industry, that for a company to survive it had to exist in competition with all others.Clinproxy, on the other hand has embraced the ...
Trial Establishes New Data Regarding Safety Of Artemisinin Combination Therapy For Pregnant Women With Malaria
A trial conducted in northwest Thailand has found that it is safe to use artemisinin combination therapy (ACT) to treat pregnant women with malaria, but that efficacy is inferior to single-drug artesunate treatment. The study, published in next week's PLoS Medicine, suggests that the ACT evaluated in the trial, artemether-lumefantrine (AL), may have lower efficacy because drug concentrations were seen to be reduced during pregnancy.
Prenatal Meth Exposure Linked To Abnormal Brain Development
A first of its kind study examining the effects of methamphetamine use during pregnancy has found the drug appears to cause abnormal brain development in children. The research is published in the April 15, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Amylin And Lilly Announce Plans To Develop Pen Device For Exenatide Once Weekly
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the companies have agreed in principle to the terms of a joint supply agreement for an exenatide once weekly pen device. Separately, the companies announced that they have initiated a phase 1/2 clinical study to examine a new exenatide once weekly suspension formulation.
The concept of outsourcing should not be new to pharmaceutical companies
The idea of outsourcing clinical trials took a dramatic increase two decades ago and continues to increase at a rapid pace. It is estimated that by 2006 close to 45% of all drug development finances will be allocated to outsourcing to such companies as Limdato, www.limdato.com. Prior to the ...
Re-Engineered Hospital Discharge Program Designed To Reduce Rehospitalization
Researchers from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) have designed a process to minimize discharge failures. The Re-Engineered Discharge (RED) program reduces hospital utilization within 30 days of discharge by over 30 percent, by redesigning the discharge workflow process. These findings appear in the February issue of the Annals of Internal Medicine. One in five hospitalizations is complicated by a post-discharge adverse event.
Geron Initiates Clinical Trial Of GRN163L In Combination With Bortezomib And Dexamethasone In Patients With Multiple Myeloma
Geron Corporation (Nasdaq:GERN) today announced that it has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.
Combating Weight Gain Caused By Antipsychotic Treatments
Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia. Unfortunately, the weight gain commonly experienced with antipsychotic treatment is an important side effect for many patients, and causes many patients to discontinue their use leading to even further problems.
The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity. In addition to on-site responsibilities each CRA is responsible for site management documentation and follow-up activities ...
New Study Shows Coaching To Patient Activation Levels Improves Disease Management Outcomes
People with chronic health conditions who receive coaching tailored to their level of health activation showed significant improvements in clinical outcomes, and experienced fewer hospitalizations and visits to the emergency room than those coached using traditional methods, according to a study published in the June issue of The American Journal of Managed Care. The study, led by Judith Hibbard, Ph.D.
Recently Published Study Demonstrates Pharmacokinetic Advantages Of ENDOMETRIN(R) Over Crinone(R) For Progesterone Supplementation
Endometrin(R) (progesterone) Vaginal Inserts, 100 mg showed clear advantages over Crinone* (progesterone gel) for progesterone supplementation, according to the results of a new pharmacokinetic (PK) study. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo and to support early pregnancy.
University Awarded £2.75 Million For Clinical Trials Research
The University of Liverpool will become one of seven national 'hubs' for developing clinical trial methodologies following an award of £2.75 million by the Medical Research Council (MRC). The MRC, in partnership with the National Institute of Health Research (NIHR), has provided £16 million of funding to establish a national network of centres which will develop new and improved methods to design, conduct, analyse and report clinical trials.
The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.
The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity. In addition to on-site responsibilities each CRA is responsible for site management documentation and follow-up activities ...
Genetic Causes Identified For Disturbances In Lipid Metabolism
Scientists of Helmholtz Zentrum Munchen led by Professor Karsten Suhre have identified new gene variants associated with disturbances in the lipid metabolism. Some of these common human gene variants are already known to be risk factors for diabetes mellitus. The pathomechanisms of diabetes have intrigued physicians and been the subject of much debate for many decades...
Case Western Reserve Awarded Nearly $500,000 From Susan G. Komen To Study Breast Cancer In Older Women
Cynthia Owusu, MD, associate professor at Case Western Reserve University and geriatric-oncologist at University Hospitals Case Medical Center, the School's primary affiliate, has received nearly $500,000 from Susan G. Komen For the Cure to fund a novel three-year study aimed at improving outcomes for older women with newly-diagnosed breast cancer...
AGA Medical Enrolls First Patient In AMPLATZER(R) Cardiac Plug Clinical Trial
AGA Medical Holdings, Inc. (AGA Medical) (Nasdaq: AGAM) announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient...
Cereprotex displayed a significant anti-edema effect in a model of closed head injury.
Cereprotex displayed a significant anti-edema effect in a model of closed head injury. It significant decreases in the degree of edema developed after injury was found following treatment postponed one hour after traumatic injury. About 35% less water accumulated in the traumatized hemisphere ...
First Evidence That Blueberry Juice Improves Memory In Older Adults
Scientists are reporting the first evidence from human research that blueberries - one of the richest sources of healthful antioxidants and other so-called phytochemicals - improve memory. They said the study establishes a basis for comprehensive human clinical trials to determine whether blueberries really deserve their growing reputation as a memory enhancer...
Updated Survival Data From Three Phase II Ipilimumab Studies Showed Almost Half Of Previously Treated Metastatic Melanoma Patients Alive Beyond 1 Year
Bristol-Myers Squibb Company (NYSE: BMY) announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV), who had previously been treated. Study results show that approximately half of patients who received ipilimumab (10 mg/kg) remained alive beyond one year. Ipilimumab is an investigational monoclonal antibody with a novel mode of action that activates the immune system to fight cancer.
Breathing Life Into Injured Lungs: World-First Technique Expands Donor Pool
For the first time in the world, transplant surgeons at Toronto General Hospital, University Health Network used a new technique to repair an injured donor lung that was unsuitable for transplant, and then successfully transplanted it into a patient. The use of this technique could significantly expand the lung donor organ pool and improve outcomes after transplantation. In their ground-breaking research, a team of lung transplant surgeons led by Dr.
In the United States, CROs receive an estimated 60% of the clinical research outsourced from pharmaceutical companies.
Typically, large CROs compete on the basis of medical and scientific expertise in specific therapeutic areas; the ability to manage large-scale trials on a global basis with strategically located facilities, by providing medical database management capabilities, providing statistical and ...
Labor Induction Need Not Increase Cesarean Risk, UCSF/Stanford Team Findings
Contrary to a belief widely held by obstetricians, inducing labor need not increase a woman's risk for cesarean section delivery in childbirth, scientists at the University of California, San Francisco and the Stanford University School of Medicine have found.
Higher Cancer Rates Found In Liver Transplant Patients Receiving Cyclosporine For Immunosuppression
Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD)...
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions of either 500 mg or 1000 mg of Rituxan or placebo for up to two treatment courses in combination with a stable dose of MTX.
Pharmalef Developments is a home for team-oriented professionals
Pharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.They entered into many collaborations with leading ...
To Evade Our Immune System Meningitis Bacteria Dress Up As Human Cells
The way in which bacteria that cause bacterial meningitis mimic human cells to evade the body's innate immune system has been revealed by researchers at the University of Oxford and Imperial College London. The study, published in Nature, could lead to the development of new vaccines that give better protection against meningitis B, the strain which accounts for the vast majority of cases of the disease in the UK.
ArQule Achieves Clinical Milestone In MiT Trial With ARQ 197 - Confirmed Tumor Response In Clear Cell Sarcoma Leads To Expanded Trial
ArQule, Inc. (NASDAQ: ARQL) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase, in MiT (Microphthalmia Transcription Factor)-associated tumors based on the achievement of a partial response, as defined by RECIST (Response Evaluation Criteria in Solid Tumors), in a patient with clear cell sarcoma.
Ethical Red Flags Raised Following Gene Therapy Research In Developing World
Early stage gene therapy clinical trials are recruiting patients from the developing world, providing medically deprived populations access to interventions that show promise but have largely unknown effects in humans. According to commentary by bioethicists at Carnegie Mellon and McGill universities published in this week's issue of The Lancet, the practice may be inconsistent with international ethics guidelines on justice.
Clinqua Inc. has embraced the concept that cooperation with other aspiring companies is the key to unlocking success in the clinical and biopharmaceutical research industry.
Clinqua is a Contract Research Organization www.clinqua.com that is attempting to change the age old notions that plagued the Clinical and Biopharmaceutical Industry, where in the past it was believed that for a company to survive it had to exist in competition with all others.
Phase 1/2 Results For Aldagen's ALD-301 Critical Limb Ischemia Clinical Study Presented At AHA
Aldagen, Inc. announced that researchers presented results from its multicenter Phase 1/2 clinical trial of ALD-301, a cell therapy being developed as a treatment for advanced critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD). In the study, ALD-301 was well-tolerated, and patients in the treatment group were shown to have increased blood flow and improved clinical status.
Tests Of Medication Used To Treat High Blood Pressure Suggest Positive Role In Potential Plaque Regression
Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque. The trial, "Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IVUS [OLIVUS], was performed on 247 angina patients with native coronary artery lesions.
Report Examines Cost-Effectiveness Of Larger Clinical Trials To Prevent Postapproval Adverse Events
"Use of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs," Health Affairs: In the Web exclusive, Shelby Reed, an associate professor of medicine at the Duke University
Injury to myelinated axons in the CNS often has a devastating outcome in terms of neuronal loss, with accompanying loss of function.
Damage to the nervous system may result from traumatic injury, such as penetrating or blunt trauma, stroke, or neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), diabetic neuropathy or senile dementia. ...
Most Kidney Dialysis Patients Not Prepared For Emergency Evacuation
Immediately after Hurricane Katrina in August 2005, the survival of more than 5,800 Gulf Coast kidney dialysis patients was threatened as the storm forced closure of 94 dialysis units. Within a month 148 of these patients had died...
Data Show Progression-Free Survival Advantage With Sutent(R) In Patients With Pancreatic Neuroendocrine Tumors
Pfizer Inc. announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas...
Novelos Therapeutics Discontinues Current Development Program For NOV-002 In NSCLC
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy...
Pharmalef Inc. is starting collaboration in development of new oral delivery platform
Pharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.Moreover, oral delivery improves patient compliance, improves treatment, ...
Romark Initiates Clinical Trial Of Alinia For Treatment Of Influenza
Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain...
FDA Advisory Committee Recommends Approval Of Multaq® (dronedarone)
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq® by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).
Crystal Structure Of Anti-Cancer Drug Shows How Drug Disables Harmful Copper In Cells
The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers. That much is known. Very little, however, is known about how the drug works at the molecular level. A new study led by Northwestern University researchers now has provided an invaluable clue: the three-dimensional structure of TM bound to copper-loaded metallochaperones.
Injury to myelinated axons in the CNS often has a devastating outcome in terms of neuronal loss, with accompanying loss of function.
Damage to the nervous system may result from traumatic injury, such as penetrating or blunt trauma, stroke, or neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), diabetic neuropathy or senile dementia. ...
Aragon Pharmaceuticals Doses First Patient In Phase 1/2 Clinical Trial Of ARN-509 For Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC)...
Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint
Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints...
Study Assesses New Surgical Procedure For Regenerating Cartilage In Damaged Knee Joints
Rush University Medical Center is testing a new procedure for regenerating damaged articular cartilage in the knee joint to relieve the pain of osteoarthritis. Rush is the only center in Illinois participating in the CAIS Phase III clinical trial.
ClinQua Inc. : The overall cost of clinical trials depends on an array of factors
In a progressive global market of supply and demand, it remains unthinkable to engage in practices that are ambitiously over-priced when there are endless opportunities to utilize more cost-efficient methods which would yield the same results. As per Mr. David Mills former ClinQua Clinical ...
Transcatheter Cardiovascular Therapeutics 2009
WHAT: Data from late-breaking clinical trials of new interventional techniques and devices will be released at TCT 2009 - Transcatheter Cardiovascular Therapeutics - the global annual scientific symposium of the Cardiovascular Research Foundation. Researchers will present a variety of new data that promises to advance the field of interventional cardiology. The TCT 2009 final program is now available at:
New Study Argues For CT Colonography As Primary Colon Cancer Screening Test
CT colonography allows radiologists to predict, with a high degree of confidence, whether or not a polyp needs to be evaluated through colonoscopy or removed through polypectomy, according to a study performed at the University of Wisconsin School of Medicine and Public Health in Madison, WI. The study included 479 patients with 739 CT colonography (CTC) detected lesions.Viev all previous articles...
Some Article Feeds provided by MedicalNewsToday.com